Rigoureux, ponctuel et fiable
Can DG Industrie Pharmaceutique ou Life Science
1430 € HT par jour
Disponibilité : Dispo : Maintenant
Disponible en part-time: Oui

Profil mis à jour le : 21/10/2020

Mobile en france

Contacter Can  Ajouter aux favoris Publier un avis
1430 € HT/j
Disponibilité : Dispo : Maintenant
Mobile en france
Can

DG Industrie Pharmaceutique ou Life Science

Paris — 58ans
 

Note Globale    

Can

58 ans

Paris

Can
DG Industrie Pharmaceutique ou Life Science

Expériences professionnelles

 

THERADIAG SA
Paris (75000)

Vice President Business Unit Theranostic

Jan 2016 - Déc 2018

France
Euro 9 million in revenue public company listed at Euronext. Specialist in developing and innovating In Vitro Diagnostic and Theranostic (combining therapy and diagnostic) assays. Product trademarks: LISA TRACKER, BioCLIA TRACKER

Develop LISA TRACKER (drug and drug antibody test for Therapeutic Drug Monitoring) sales in France and internationally. Establish Therapeutic Drug Monitoring as key element to personalize treatment of patients receiving biotherapy.

Key achievements:

  • Orchestrated double digit sales growth over four quarters winning new hospital clients.
  • Confirmed LISA TRACKER as market leader in French university hospitals with emphasis on assay quality and service.
  • Enabled top ten pharmaceutical companies to win UniHA (MSD, Pfizer) and AGEPS (Biogen) tenders, respectively.
  • Incorporated in 2017 Therapeutic Drug Monitoring into therapy guidelines (France, US, Australia, Canada).

APTALIS Pharma SAS,
Paris (75000)

Head Commercial Development & Export Operations

Jan 2013 - Jan 2016

France
Euro 800 million in revenue specialty pharmaceutical company marketing drugs for gastrointestinal diseases and disorders.

Develop export sales with focus on Europe and Middle East Markets. Provide guidance and have hands-on approach where required. Introduce new Rx Product. Establish OTC / Food supplement product line.

Key achievements:

  • Rolled out successfully PYLERA (eradication of Helicobacter Pylori) in Europe and 10+ international markets.
  • Accelerated Middle East PYLERA product registration by shifting from US dossier to EU dossier.
  • Developed and implemented OTC strategy for LACTEOL (Lactobacillus LB) guiding 30+ people contract sales force.
  • Integrated Aptalis product portfolio into three different companies: LACTEOL into Adare Pharmaceuticals, PYLERA into Allergan and mature products including colistin (COLOBREATHE) for the treatment of Cystic Fibrosis into Teva.

Société de Conseil et de Management de Transition

Founder

Jan 2011 - Jan 2013

Munich, Germany
Interim-Management, Business Angel

Attract investors for high-potential start-up companies in Germany and Europe. Provide consulting service to companies on how realize growth.

Key achievements:

  • Found investor for bio fast food company in Germany.
  • Advised consulting firm Alchemy Network on strategy and applied successfully growth principles with 10+ clients.

IMS Health,

Regional European Key Account Director EMEA

Jan 2008 - Déc 2010

Munich/Frankfurt, Germany

Euro 3 billion in revenue company providing information, services and technology to the health care industry.

Act as strategic partner to three leading multinational pharma companies. Transform profoundly IMS Health’s data provider image. Out of 50 top IMS accounts these three clients were exceptionally successful during financial crisis and beyond.

Drive within IMS Health’s matrix organization projects in Pharma Strategy, Sales Force Efficiency, Launch Excellence and Pharmerging Markets to maximize client competitiveness.

Key achievements:

  • Generated growth with all three clients during economic crisis and realized Euro 40 million in revenue.
  • Positioned IMS with clients as top of the mind strategic and operational partner.
  • Initiated several USD single digit million projects with top ten US account. Sold six-figure projects to other two clients.

Grünenthal Regional Office,

General Manager Middle East

Jan 2005 - Jan 2008

Beirut, Lebanon
(ten countries)


Grünenthal GmbH,

Area Director

Jan 2000 - Jan 2005

Aachen, Germany
(Analgesics, Oral Contraceptives, Corticoids)

Euro 800 million in revenue family-owned pharmaceutical company leader in pain management.

Make Export Operations growth engine of company enabling creation of Regional Hubs in Middle East, Latin America and CEE.

Direct as General Manager strategy and commercial operations assuming full P&L accountability. Report regional financial results on monthly basis. Headcount responsibility for 70+ employees including 5 Country Managers. Guide country organizations and network of distributors. Supervise local manufacturers and corporate production sites. Reported to Corporate Board.

Key achievements:

  • Created as Area Director Middle East, Africa and Australasia a responsive and market-driven export organization. Increased sales from Euro 6.5 to 16 million realizing 30+% profit margin. Developed Australian market implementing second brand strategy for flag ship analgesic. Positioned original brand and a generic version via separate channels.
  • Improved substantially productivity in the Middle East applying lean management principles. Attained 20% profit margin after creation of Regional Office from scratch in 2005.
  • Excelled with Business Development by convincing Regional Hub countries to introduce oral contraceptive positioned as Beauty Pill, initiated in-house OTC development of dermatological cream for irritated skin (cosmoceutical) and kicked-off in-licencing discussions to introduce herbal product line in CNS and Women’s Health.

Groupe Fournier,
Paris (75000)

Head of Development Unit Immunology

Jan 1998 - Jan 2000

France


Groupe Fournier,
Paris (75000)

Group Product Manager Development Products

Jan 1997 - Jan 1998

France


Fournier Pharma GmbH,

Sales Director

Jan 1996 - Jan 1997

Hamburg, Germany
North Germany

Euro 500 million in revenue family owned pharmaceutical company commercializing lipid lowering drugs and wound plasters.

Provide strategic and operational direction for key R&D projects in Immunology. Realize Euro 6 million sales in North Germany and lead Sales Team to first position in Euro 16 million German affiliate.

Advised Immunology project team on forecasting, financial viability (Net Present Value) and commercialization. As Head of Development Unit accountable for project progress with focus on strategy, board briefings, marketing plans. Reported to CEO.

Key achievements:

  • Pushed two Immunology molecules into clinical phase.
  • Allocated R&D Euro 15 million Immunology budget to projects with highest return-on-investment.

Hoechst AG / Roussel Uclaf,
Paris (75000)

International Product Manager Cardiovascular

Jan 1994 - Déc 1995

France


Hoechst AG / Albert Roussel,

Sales Representative

Jan 1993 - Déc 1994

Münster, Germany
(Antibiotics, Cardiovasculars)


Hoechst AG / Albert Roussel,

Jan 1990 - Déc 1992

Wiesbaden, Germany
(Antibiotics)

Euro 25 billion in revenue specialty pharmaceutical company. Market leader in Diabetes, Infectious Diseases and Cardiology.

Direct international launch of Roussel Uclaf’s top priority ACE (angiotensin converting enzyme) Inhibitor.

Trained and mentored local product managers for ACE Inhibitor launch in Europe, Latin America, Australasia and Japan.

Key achievements:

  • Succeeded ‘Lancet’ publication of TRACE mortality study using flagship ACE Inhibitor Trandolapril (tradename ODRIK).
  • Launched as sales representative very successfully top priority ACE inhibitor and four line extensions in antibiotics.
  • Conducted phase IIIb clinical trial with antibiotic suspension in paediatric patients.

Stadtkrankenhaus Hanau

– Intern Fellow

Jan 1988 - Jan 1990

Germany
(hospital physician)


Merck Santé
Lyon, France

Directeur Médical

Jan 2019 - Aujourd'hui

MERCK SANTE (Merck KGaA), Lyon, France

Realized turnaround of 50+ staff medical department to become fully appreciated as business partner in five therapeutic areas (oncology, neurology, fertility, endocrinology and general medicine), in its function as medical / scientific information provider and as RWE (Real World Evidence) data specialist.

MEDICAL DIRECTOR FRANCE (2019 to 2020)

Refocused activities before and especially during COVID-19 lockdown developing digital solutions.

¨ Designed and get approved Early Access Programme - ATU - BAVENCIO (Avelumab) in first line maintenance therapy of bladder cancer patients in alliance with Pfizer. First patient in: July 2020.

¨ Received approval by authorities of recommendation of use programme - RTU - with OVITRELLE (Choriogonadotropine alfa) in infertile male patients.

¨ Obtained MAVENCLAD (Cladribine) approval in highly active relapsing Multiple Sclerosis patients in May 2020 after an initial rejection in 2018.

¨ Reconfirmed Merck’s medical and scientific leadership position in fertility during lockdown period by establishing targeted scientific partnerships with fertility centers all over France.

¨ Coached and empowered the medical team, from first reports to new hires, to embrace the right attitude and to transform routine habits into a new and appropriate mindset focusing on the best possible support to health care providers and patients.


Formation

 

1988     Johannes Gutenberg Universität Mainz - Médecine

Langues

 

Allemand : Bilingue ou langue maternelle

Français : Bilingue ou langue maternelle

Anglais : Bilingue ou langue maternelle

Chargement...